Analyst Insights

Roth Capital Reiterates Buy On Cytori On Encouraging Notice Of Intent From BARDA

In a research note released yesterday, Roth Capital analyst Joseph Pantginis maintained coverage with a Buy rating on shares of Cytori Therapeutics (CYTX), and a price target of $10, following yesterday’s …

AcelRx: We Would Be Buyers Ahead Of The PDUFA, Says Roth Capital

In a research report released yesterday, Roth Capital analyst Ed Arce reiterated a Buy rating on AcelRx Pharmaceuticals Inc. (ACRX) with a price …

Roth Capital Maintains Buy On Landec Following Investor Meetings With CEO

In a research note issued today, Roth Capital analyst Anton Brenner maintained a Buy rating on Landec Corporation (LNDC) with a price target …

Feltl Maintains Hold On Atmel Following The Acquisition Of Newport Media

In a research note released this morning, Feltl and Company analyst Jeffrey Schreiner maintained a Hold rating on Atmel Corporation (ATML) with a price …

Cesca Represents An Undervalued Player With Significant Upside, Says H.C. Wainwright

In a research note released earlier today, H.C.

Roth Capital Maintains Buy On RedHill, Boosts Price Target To $24

In a research note issued this morning, Roth Capital analyst Scott Henry maintained a Buy rating on RedHill Biopharma (RDHL) and raised his price target …

Canaccord Initiates Buy On Abengoa; Sees 31% Potential Upside For Stock

In a research report published yesterday, Canaccord Genuity analyst John Quealy initiated coverage on Abengoa Yield (ABY) shares. Quealy issued a Buy rating …

William Blair Reiterates Outperform On Fastenal; Sees High Growth For Upcoming Months

In a research note released yesterday, William Blair analyst Ryan Merkel reiterated an Outperform rating on Fastenal Company (FAST) as estimates predict a …

Wedbush Reiterates Neutral Rating On PetSmart As Competition Increases And Consumer Behavior Changes

In a research note released Monday, Wedbush analyst Seth Basham maintained a Neutral rating on PetSmart (PETM) and raised his price target to …

William Blair Maintains Outperform On BioDelivery Following Positive Phase III Results

In a research report published Monday, William Blair analyst Tim Lugo maintained an Outperform rating on BioDelivery Sciences International Inc. (BDSI) and raised …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts